Previous studies have generally investigated germline TP53 mutations in affected individuals, such as women developing breast cancer before 31 years of age, individuals who met the criteria for LFS or Li-Fraumeni-like syndrome, or unaffected individuals from a family with a known TP53 pathogenic or likely pathogenic (P/LP) variant [6, 7]. The gene discussed is TP53; the disease is breast carcinoma.